AVADEL PHARMACEUTICALS PLC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
Country Ireland
Business Address 10 EARLSFORT TERRACE, DUBLIN 2, , D02 T380
Mailing Address 16640 CHESTERFIELD GROVE ROAD, CHESTERFIELD, MO, 63005
Phone 636-449-1830
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
-$48.83M
Net Income
$90.39M
Total Liabilities
$51.37M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
Material Events
8-K Acquisition February 12, 2026
High Impact
- AVADEL PHARMACEUTICALS PLC was acquired by Alkermes plc, ending its independent public trading status.
- Former shareholders received $21.00 in cash per share, plus a Contingent Value Right (CVR) for a potential additional $1.50 per share.
8-K Acquisition January 20, 2026
High Impact
- Avadel Pharmaceuticals is nearing acquisition by Alkermes plc, integrating its FDA-approved narcolepsy treatment, Lumryz, into Alkermes' neuroscience portfolio.
- Lumryz is expected to become a significant growth driver and revenue source for Alkermes.
8-K Acquisition January 12, 2026
High Impact
- AVADEL shareholders overwhelmingly approved the acquisition by Alkermes plc.
- Over 95% of voting shareholders supported the main acquisition scheme.
Related Companies
Companies in the same industry (SIC: 2834)
Werewolf Therapeutics, Inc.
HOWL Pharmaceutical Preparations
Zenas BioPharma, Inc.
ZBIO Pharmaceutical Preparations
Centessa Pharmaceuticals plc
CNTA Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI Pharmaceutical Preparations
VERTEX PHARMACEUTICALS INC / MA
VRTX Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.